Maintaining technical quality of care in the introduction of Cyclofem in a national family planning program: findings from Indonesia.
This paper discusses the technical dimensions of "quality of care" in contraceptive service delivery in both the Cyclofem Introductory Trial, as well as in routine service delivery of other injectables in Indonesia. Although the quality of care in the Cyclofem trial was generally acceptable, substantial weaknesses in screening, clinical technique, the management of side-effects, and knowledge concerning re-injection time frames were identified in the provision of injectable contraceptives in routine service delivery. The findings suggest that in order for Cyclofem and other injectables to be delivered in the routine program with an adequate standard of care, considerable managerial adaptation and strengthening of providers' technical capabilities would be necessary prior to actual introduction. This would include providing training and updated technical guidelines concerning both Cyclofem and other contraceptives to providers, with an emphasis on technical issues including contraceptive indications and contraindications, re-injection time frames, maintenance of asepsis and the management of side-effects. Strengthening the existing management information system and logistics systems to facilitate differentiation between injectable contraceptives provided by the program so as to ensure sufficient supplies of both contraceptives and associated materials such as needles and syringes will also be necessary.
Lubis
F
F
Yayasan Kusuma Buana, Jakarta, Indonesia.
Fajans
P
P
Simmons
R
R
D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects; D000075202:Contraindications; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005193:Family Planning Services; D005260:Female; D006801:Humans; D007214:Indonesia; D007267:Injections; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects; D011787:Quality of Health Care
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004958:Estradiol; C034528:CycloProvera; D017258:Medroxyprogesterone Acetate